CTKB vs PACB: stock comparison and AI forecast
Cytek Biosciences, Inc. (CTKB) and Pacific Biosciences Of California, Inc. (PACB) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CTKB Cytek Biosciences, Inc.
- Price
- $5.40 +9.8% · 6M
- Market Cap
- $702M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
PACB Pacific Biosciences Of California, Inc.
- Price
- $2.55 +49.1% · 6M
- Market Cap
- $793M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- PACB is 1.1 times larger than CTKB by market capitalization ($793M against $702M).
- Over the last six months PACB returned +49.1% and CTKB +9.8%.
- CTKB turns -39.1% of its revenue into net income, against -82.5% for PACB.
- Both companies share the SEC industry classification Laboratory Analytical Instruments.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CTKB | PACB |
|---|---|---|
| Market Cap | $702M | $793M |
| P/B Ratio | 2.18x | – |
| EPS | $-0.64 | $-0.38 |
| Book Value/Share | $2.47 | – |
| Revenue/Share | $1.60 | $0.51 |
| FCF/Share | $-0.10 | $-0.40 |
Profitability & Margins
| Metric | CTKB | PACB |
|---|---|---|
| ROE | -25.3% | – |
| ROA | -18.2% | -17.5% |
| ROIC | -12.2% | -19.5% |
| Gross Margin | 54.8% | 36.4% |
| Operating Margin | -21.1% | -83.5% |
| Net Margin | -39.1% | -82.5% |
| EBT Margin | -20.4% | -82.0% |
| Tax Rate | -97.5% | -0.6% |
Financial Health
| Metric | CTKB | PACB |
|---|---|---|
| Current Ratio | 4.46x | 4.92x |
| Quick Ratio | 3.84x | 4.03x |
| D/E Ratio | 0.39x | – |
| Financial Leverage | 1.39x | – |
| Interest Coverage | -24.3x | -5.0x |
| Working Capital | $294M | $270M |
Cash Flow
| Metric | CTKB | PACB |
|---|---|---|
| Operating Cash Flow | -$7M | -$118M |
| Free Cash Flow | -$13M | -$123M |
| Capital Spending | -$7M | -$5M |
| FCF/Sales | -6.5% | -77.5% |
| CapEx/Sales | 3.3% | 3.4% |
Operational Efficiency
| Metric | CTKB | PACB |
|---|---|---|
| Asset Turnover | 0.47x | 0.21x |
| Receivables Turnover | 3.5x | 5.1x |
| Inventory Turnover | 1.8x | 1.7x |
| Fixed Assets Turnover | 10.1x | 5.9x |
| Days Sales Outstanding | 104 days | 71 days |
| Days Inventory | 203 days | 220 days |
| Payables Period | 0 days | 69 days |
| Cash Conversion Cycle | 307 days | 222 days |
Income Statement
| Metric | CTKB | PACB |
|---|---|---|
| Total Revenue | $208M | $159M |
| Operating Income | -$44M | -$133M |
| Net Income | -$81M | -$131M |
| R&D Expense | $38M | $88M |
| SG&A Expense | $156M | $130M |
| Cost of Goods Sold | $94M | $101M |
Dividend & Shareholder Information
| Metric | CTKB | PACB |
|---|---|---|
| Shares Outstanding | 130M | 311M |
CTKB vs PACB: stock comparison and AI forecast
Which is bigger, CTKB or PACB?
PACB is 1.1 times larger than CTKB by market capitalization ($793M against $702M).
Which stock performed better over the last six months, CTKB or PACB?
Over the last six months PACB returned +49.1% and CTKB +9.8%.
Which one does Intratio's AI model rank higher, CTKB or PACB?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.